Enhancing Access to Affordable Healthcare - HIV

This entry highlights Strides Pharma’s commitment to expanding access to affordable, high-quality HIV treatment worldwide. Through voluntary licensing agreements with ViiV Healthcare and the Medicines Patent Pool (MPP), Strides has developed and supplied generic versions of Dolutegravir (DTG)-based regimens, including innovative paediatric formulations tailored for children living with HIV in low- and middle-income countries.

Between 2020 and 2023, Strides supplied over 540 million doses of the WHO-recommended Tenofovir/Lamivudine/Dolutegravir (TLD) regimen, with a target of reaching 800 million doses by FY2025. The company’s manufacturing sites in India and Kenya are WHO-prequalified and meet stringent international standards, including approvals from the US FDA and UK MHRA.

Strides has worked closely with global health partners such as the Global Fund, USAID/PEPFAR, UNICEF, UNITAID, and the Clinton Health Access Initiative to integrate its medicines into key international treatment and procurement programs. Today, Strides’ DTG-based therapies are registered in over 123 countries and form a crucial part of national HIV programs, particularly in regions hardest hit by the epidemic.

This initiative directly addresses long-standing gaps in treatment availability — helping to lower the cost of vital HIV medicines and improve access for millions of patients, with a strong focus on paediatric care. By combining technical innovation in drug formulation with large-scale manufacturing and distribution, Strides is helping set a new benchmark for how the generics industry can deliver meaningful public health impact on a global scale.